CJC-1295 Ipamorelin Results

What results did research actually measure for CJC-1295 and ipamorelin?

The published results are blood-hormone changes over time, not body-composition outcomes. In a phase 1 study, CJC-1295 produced a dose-dependent rise in GH of roughly 2 to 10 fold and in IGF-1 of roughly 1.5 to 3 fold above baseline (Teichman et al., 2006). Ipamorelin, studied separately, was characterized as a GH secretagogue that raised GH selectively (Raun et al., 1998). When people search "CJC-1295 ipamorelin results," the honest answer from the literature is a hormone curve, not a scale number.

That distinction matters. A GH or IGF-1 increase in a trial is a measured biomarker. Whether that biomarker moves fat, lean mass, recovery, or sleep in humans is a separate question the cited trials did not answer for this pairing.

How fast does CJC-1295 raise GH and IGF-1, and how long does it last?

GH rises within hours; IGF-1 climbs over days and can stay above baseline for roughly two weeks after a single CJC-1295 dose. Teichman et al. (2006) reported that a single administration of CJC-1295 sustained raised GH and IGF-1 concentrations, with IGF-1 remaining raised for days to about 2 weeks. This long tail is the feature that separated CJC-1295 from short-acting GH-releasing peptides in that study.

Ipamorelin acts on a faster timescale. As a ghrelin-receptor agonist studied in the pituitary model, it drove an acute GH pulse (Raun et al., 1998). The two therefore describe different parts of the same curve: a sharp pulse versus a sustained elevation.

Trial-measured hormone timeline

These are measured hormone changes from named trials, not a schedule to follow. Any personal protocol belongs with a qualified clinician.

What doses did the research use?

The cited trials tested defined amounts and measured the hormone response, which is different from a recommendation. Teichman et al. (2006) evaluated single ascending doses of CJC-1295 and recorded the GH and IGF-1 responses described above. Raun et al. (1998) characterized ipamorelin's GH-releasing activity in a preclinical model. This page reports what those studies administered and observed; it does not tell any reader what to take, when, or how. Dose decisions require a licensed clinician who can weigh individual factors and current labs.

Why are CJC-1295 and ipamorelin studied together?

They engage two separate receptor systems, so researchers pair them to probe complementary GH-axis signals. CJC-1295 works as a growth-hormone-releasing-hormone analog and produced sustained GH and IGF-1 elevation in humans (Teichman et al., 2006). Ipamorelin works through the ghrelin/GH-secretagogue receptor and produced a selective GH pulse without the cortisol and prolactin rise seen with some other secretagogues in the studied model (Raun et al., 1998).

The rationale in the literature is mechanistic complementarity: one sustains, one pulses. That is a pharmacology observation, not evidence of a specific body-composition result in humans.

Do these hormone changes translate to fat loss or muscle gain?

The cited trials did not measure body composition for this pairing, so any such claim goes beyond the evidence. For context on where GH-axis peptides have shown a measured tissue outcome, tesamorelin, a different GHRH analog, reduced visceral adipose tissue by about 15 percent in a controlled trial (Falutz et al., 2007). That is a separate compound with its own endpoint and does not transfer to CJC-1295 plus ipamorelin.

The careful reading: CJC-1295 and ipamorelin have documented hormone-kinetic results (Teichman et al., 2006; Raun et al., 1998), and human outcome data for the combination is limited. Statements about physique change extrapolate past the trials named here.

What are the known limits and safety signals in the research?

Human data is limited and short in duration, and GH-axis stimulation is not free of metabolic signals. The CJC-1295 human record centers on hormone kinetics over a single-dose window (Teichman et al., 2006) rather than long-term outcomes. More broadly, GH secretagogues can shift glucose handling: in an older-adult trial, the oral secretagogue MK-677 raised fasting glucose and reduced insulin sensitivity (Nass et al., 2008). That finding is a reason blood-glucose monitoring and clinician oversight belong in any research context, even though MK-677 is a different molecule.